Chevy Chase Trust Holdings LLC Reduces Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Chevy Chase Trust Holdings LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,017 shares of the company's stock after selling 1,132 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.05% of IDEXX Laboratories worth $17,785,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Geode Capital Management LLC increased its stake in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after purchasing an additional 40,349 shares during the period. Franklin Resources Inc. increased its stake in shares of IDEXX Laboratories by 2.5% during the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after buying an additional 34,305 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of IDEXX Laboratories by 0.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock valued at $379,875,000 after buying an additional 2,463 shares during the period. International Assets Investment Management LLC increased its stake in shares of IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after buying an additional 527,460 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after buying an additional 316,048 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Up 0.4 %

NASDAQ IDXX traded up $1.93 during trading on Wednesday, hitting $450.99. The company's stock had a trading volume of 499,898 shares, compared to its average volume of 704,909. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a market cap of $36.93 billion, a PE ratio of 42.27, a P/E/G ratio of 3.35 and a beta of 1.37. The business's 50 day simple moving average is $430.91 and its 200-day simple moving average is $452.43. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39.

Analyst Ratings Changes

Several equities analysts have recently commented on IDXX shares. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Finally, Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

Insiders Place Their Bets

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,330 shares of company stock valued at $6,161,276. 2.18% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.